In 2025, Complete Omics advanced toward comprehensive measurement of the human proteome in our Complete360 platform, positioning our platforms to transform proteomics into a scalable clinical infrastructure for early detection, therapeutic discovery, and precision medicine.
Complete360® Achieves 10,000+ Protein Quantification While Valid-NEO® Enters Clinical Cancer Applications
In 2025, Complete Omics reached a defining technological milestone with the Complete360® multi-omics platform achieving ultra-deep molecular coverage of human plasma, enabling the simultaneous detection and quantitative measurement of more than 10,000 proteins and over 2,100 small molecules from a single patient sample.
This achievement represents one of the most comprehensive molecular measurements ever achieved from human plasma and marks a major step toward realizing the long-standing vision of systematically measuring the functional molecular layer of human biology at clinical scale.
Ultra-Deep Measurement of the Human Plasma Proteome
Human plasma is one of the most information-rich biological samples, yet it is also one of the most technically challenging matrices for proteomics due to the enormous dynamic range of protein abundance. Historically, this complexity limited the number of measurable proteins in blood.
Through years of technological innovation—including optimized protein enrichment strategies, advanced mass spectrometry acquisition methods, and AI-assisted data analysis—the Complete360® platform was engineered to progressively expand the measurable depth of the plasma proteome.
By 2025, these efforts culminated in a platform capable of simultaneously quantifying:
- 10,000+ proteins across the plasma proteome
- ~2,100 metabolites and lipids (small molecules)
- large-scale proteome–metabolome interaction networks
This level of molecular coverage enables researchers and clinicians to observe biological processes across multiple molecular layers simultaneously, supporting applications ranging from early disease detection and biomarker discovery to therapeutic response monitoring and drug development.
Advancing Toward the Comprehensive Measurement of Human Disease
The Complete360® milestone reflects nearly two decades of scientific development beginning with early work in targeted proteomics and biomarker validation. The platform is designed not only for deep molecular discovery but also for reproducible large-scale clinical studies, enabling systematic molecular profiling across diverse diseases and patient cohorts.
By expanding the measurable portion of the human proteome and metabolome from blood samples, Complete360® provides a powerful foundation for building the proteomic layer of precision medicine.
Valid-NEO® Enters Direct Clinical Applications
At the same time, another major milestone was achieved in 2025: the Valid-NEO® platform began entering direct clinical applications in cancer patients.
Valid-NEO® is a targeted multi-omics system designed to detect and quantify cancer neoantigens directly from clinical samples using sensitive mass spectrometry–based approaches. Unlike prediction-only strategies that rely solely on genomic sequencing, the platform enables direct experimental confirmation of mutation-derived peptides that can serve as therapeutic targets.
By 2025, Valid-NEO® technologies were being applied in clinical collaborations to guide therapeutic strategies for patients undergoing precision cancer immunotherapy. Early applications have demonstrated promising results, supporting the identification of actionable neoantigen targets and enabling more precise immune-directed treatments for individual patients.
A Dual Platform Milestone
The simultaneous progress of Complete360® and Valid-NEO® in 2025 highlights the broader technological vision behind Complete Omics.
While Complete360® provides a global molecular measurement infrastructure capable of profiling thousands of proteins and metabolites, Valid-NEO® delivers ultra-targeted validation of immunotherapy targets at the peptide level.
Together, these platforms represent two complementary pillars of the company’s mission: enabling deep molecular measurement of human biology while translating those measurements into actionable therapeutic strategies.
The achievements of 2025 therefore mark an important step toward a future in which comprehensive molecular measurement can guide earlier disease detection, more precise therapies, and next-generation personalized medicine.
At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr.